DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

NCT04963231 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

164

Enrollment

INDUSTRY

Sponsor class

Conditions

Genetic Obesity

Interventions

DRUG: Setmelanotide
DRUG: Placebo

Sponsor

Rhythm Pharmaceuticals, Inc.